viral load

Netivudine is a potent nucleoside reverse transcriptase inhibitor (NRTIs), a nucleoside analogue with anti-varicella zoster virus activity that can be used to treat human immunodeficiency virus (HIV) infection. Netivudine works by inhibiting reverse transcriptase, which reduces viral load in the body and slows the progression of the disease through its inhibitory effect.

ATV006 has antiviral activity and can be used in research on the treatment of viral infections.

Zanamivir amine, a neuraminidase inhibitor, exhibits antiviral activity by effectively curbing the proliferation of influenza viruses. Clinically, it is utilized to suppress influenza infections by interfering with the viral replication process, thereby reducing viral load.

Ganglioside GM1 asialo is a component of cellular lipid rafts and can be formed by the cleavage of the sialic acid residue from ganglioside GM1 by neuraminidase. Ganglioside GM1 asialo is a glycolipid receptor for P. aeruginosa flagellin and stimulates defensive responses in host cells, including extracellular ATP release, calcium mobilization, and ERK1/2 phosphorylation when stimulated by flagellin and an anti-ganglioside GM1 asialo antibody. The percentage of ganglioside GM1 asialo-positive natural killer (NK) and CD8+ T cells in lung is increased in a mouse model of respiratory syncytial virus (RSV) infection compared with healthy animals. Depletion of ganglioside GM1 asialo-positive NK and T cells reduces IFN-γ levels in the lung, reduces weight loss, and increases lung viral load in RSV-infected mice. Ganglioside GM1 asialo mixture contains ganglioside GM1 asialo molecular species with C18:1 and C20:1 sphingoid backbones.

Remdesivir, also known as GS-5734, is a prodrug form of the antiviral nucleoside analog GS-44152. Remdesivir is a broad spectrum anti-viral drug that has shown to inhibit SARS-CoV-2, in vitro and in vivo. Efficacy of remdesivir against Ebola virus has been demonstrated. Remdesivir inhibits SARS-CoV-2 replication, reduces viral load, and exerts protective effects in SARS-CoV-2 infected animals. Remdesivir also reduces the pathological process, alleviates mild symptoms, and improves pulmonary lesions in SARS-CoV-2-infecetd animals. Remdesivir has been used as a compassionate drug for treating COVID-19 patients. *******WARNING****** Our product remdesivir is a pure chemical solid powder which is only for laboratory research use, NOT FOR HUMAN OR PATIENT USE

Casirivimab (REGN10933), a human monoclonal antibody targeting the SARS-CoV-2 virus responsible for COVID-19, demonstrates reduced efficacy against emerging variants. When combined with Imdevimab, it significantly lowers viral load and enhances disease outcomes [1].

Imdevimab (REGN10987), a human monoclonal antibody designed to neutralize the SARS-CoV-2 virus responsible for COVID-19, demonstrates reduced efficacy against emerging COVID-19 variants. When combined with Casirivimab, it effectively reduces viral load and enhances disease management [1].

Suvizumab (KD-247), a neutralizing antibody against HIV-1, effectively neutralizes strains HIV-1 MN, HIV-1 SF2, and HIV-1 89.6, exhibiting IC50 values of 0.1 µg mL, 1.0 µg mL, and 0.2 µg mL, respectively. It demonstrates a significant reduction in viral load, indicating its efficacy in preventing HIV infection. Suvizumab is also well-tolerated, further supporting its potential as a preventative treatment for HIV [1] [2].

Olgotrelvir is an antiviral agent [1]. It inhibits viral replication by targeting key viral enzymes, thereby reducing the viral load in infected cells. The compound exhibits specificity for its target enzymes, which minimizes off-target effects and enhances its therapeutic profile. Clinical studies demonstrate its efficacy against a range of viral pathogens.

ATV041, an orally active compound that combines features of Ibuprofen and nucleotide analogues, enhances the oral pharmacokinetic (PK) profile and tissue distribution, exhibiting anti-mouse hepatitis virus (MHV) activity. The compound demonstrates a dose-dependent reduction in viral load, tissue damage, and virus-induced inflammation [1].

F9170, an antiviral peptide derived from the HIV-1 envelope glycoprotein (amino acids 789-803), targets the LLP1 domain in the virus's envelope protein cytoplasmic tail. This interaction inhibits HIV-1 IIIB infection in MT-2 cells, evidenced by an EC50 value of 0.19 µM. Additionally, at a dosage of 3 mg/kg, F9170 significantly lowers plasma viral load in rhesus macaques infected with simian HIV (SHIV).